Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Cardiotoxicity 6Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma 3Neuroblastoma 2Lymphoma, Large-Cell, Anaplastic 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Ganglioneuroblastoma 2Burkitt Lymphoma 2Blast Crisis 2Sezary Syndrome 1Sarcoma, Synovial 1Sarcoma, Myeloid 1Rhabdoid Tumor 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1PRETEXT I Hepatoblastoma 1Osteosarcoma 1Neurofibrosarcoma 1Myeloproliferative Disorders 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Localized Extraskeletal Ewing Sarcoma 1Liposarcoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Doxorubicin 17Ifosfamide 16Radiotherapy 10Filgrastim 5Imatinib Mesylate 4Etoposide 4Chemotherapy, Adjuvant 4pazopanib 3Vincristine 3Neoadjuvant Therapy 3Dactinomycin 3Cyclophosphamide 3Carboplatin 3pegfilgrastim 2cixutumumab 2brostallicin 2belinostat 2Trabectedin 2Sunitinib 2Radiotherapy, Conformal 2Radiation Dose Hypofractionation 2Epirubicin 2Diathermy 2temsirolimus 1soblidotin 1selinexor 1saracatinib 1romidepsin 1ribociclib 1reolysin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Fibrosarcoma × Razoxane × Clear all
NCT02584309 2023-11-07

Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

Washington University School of Medicine

Phase 2 Completed
73 enrolled 11 charts
Sarcoma

Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡